Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$0.06 and traded as low as C$0.06. Hemostemix shares last traded at C$0.06, with a volume of 19,802 shares trading hands.
Hemostemix Trading Up 10.0%
The company has a current ratio of 0.24, a quick ratio of 0.48 and a debt-to-equity ratio of -66.09. The firm has a market cap of C$10.88 million, a PE ratio of -1.90 and a beta of 0.18. The company’s 50-day moving average is C$0.06 and its 200 day moving average is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
